Gain Therapeutics, Inc. GANX

GANX Company Overview

Gain Therapeutics, Inc. is a biotechnology company focused on the discovery and development of allosteric small-molecule therapies for diseases caused by protein misfolding. The company operates primarily in the biopharmaceutical and precision medicine sectors, with a strategic emphasis on neurodegenerative and lysosomal storage disorders. Gain Therapeutics uses its proprietary computational discovery platform, Magellan™, to identify binding sites on structurally altered proteins and develop compounds designed to restore protein function and stability. The company’s principal revenue drivers currently consist of research and development activities, strategic collaborations, and capital market financing, as it has not yet commercialized a therapeutic product.

The company’s lead therapeutic candidate is GT-02287, an orally administered small molecule being developed for Parkinson’s disease associated with GBA1 mutations. Gain Therapeutics has also pursued programs targeting rare metabolic and central nervous system disorders involving protein misfolding mechanisms. Founded in 2017, the company evolved from a platform-based drug discovery enterprise into a clinical-stage biotechnology company focused on precision neurology. Gain Therapeutics became publicly traded on the Nasdaq Capital Market under the ticker GANX following a business combination and subsequent public listing process.